# US 2021/0275505 A1 · Oxazolidinone for treatment of inffections with mycobacterium tuberculosis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0275505 A1
- Document ID: US20210275505A1
- Status: Published application
- Kind: A1
- Application number: 17/326,166
- Filed: 2021-05-20
- Published: 2021-09-09
- Earliest claimed: 2016-02-17
- Assignees: The Johns Hopkins University; University of St. Thomas
- Applicants: The Johns Hopkins University; University of St. Thomas
- Inventors: Gyanu Lamichhane; J. Thomas Ippoliti
- Web page: https://patentgrep.com/patent/US20210275505A1

## CPC

- A61K 31/4245: Oxadiazoles
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 31/422: not condensed and containing further heterocyclic rings
- A61P 31/06: for tuberculosis
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention is a method of treating or preventing Mycobacterium tuberculosis infection in a subject by administering to the subject an effective amount of oxazolidinone, specifically (N—(((S)-3-(dibenzo[b,e][1,4]dioxin-7-yl)-2-oxooxazolidin-5-yl)methyl)acetamide) or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof.

## Claims

### Claim at position 1

-8. (canceled)

### Claim 9

A method for treating or preventing a Staphylococcus aureus or an Enterococcus faecalis infection in a subject in need thereof, the method comprising administering to the subject an effective amount of (N—(((S)-3-(dibezo[b,e][1,4]dioxin-7-yl)-2-oxooxazolidin-5-yl)methyl)acetamide) or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof.

### Claim 10 (depends on 9)

The method of claim 9 wherein the subject is a human.

### Claim 11 (depends on 9)

The method of claim 9 wherein the subject is an animal.

### Claim 12 (depends on 9)

The method of claim 9 further administering at least one or more antimicrobial compounds.